Global Huperzine A Market, Forecast to 2026

February 2020 | 113 pages | ID: GF6DAF3894DDEN
Gen Consulting Company

Abstracts

Huperzine A is a substance purified from a plant called Chinese club moss. It is commonly used as a dietary supplement to improve memory and mental function in people with Alzheimer's disease, other types of dementia, age-related memory loss, and other conditions. According to Gen Consulting Company, global huperzine A market is expected to expand at a CAGR of 6.68% over the forecast period i.e. 2020-2026. Growing potential for huperzine A in therapies for Alzheimer’s disease is the chief contributor for the growth of the market.

Key players profiled in this report are:

• Cisen Pharmaceutical Co., Ltd.
• Beijing Hwells Pharmaceutical Co., Ltd.
• Shanghai Fudan Forward Pharmaceutical Co., Ltd.

Other companies in the market include Debiopharm Group, XYMOGEN, Inc., Xel Pharmaceuticals, Inc., Hainan Lingkang Pharmaceutical Co., Ltd., Simcere Pharmaceutical Group, Henan Taloph Pharmaceutical Stock Co., Ningbo Liwah Pharmaceutical Co., Ltd., Ningbo Green-Health Pharma-ceutical Co., Ltd, Shenzhen Zhonglian Pharmaceutical Co., Ltd., Wanbang Pharmaceutical Group Co., Ltd., Zhejiang Judu Pharmaceutical Group Co.,Ltd., Zhejiang Zhenyuan Pharmaceutical Co., Ltd., Yaoyou Chongqing Pharmaceutical Co., Ltd., etc.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth rate of huperzine A in these regions, from 2020 to 2026, covering North America, Europe, Asia-Pacific and RoW. China reckoned as the most significant regional market and is anticipated to develop at a 6.8% CAGR from 2020 to 2026. Growing incidence of the Alzheimer’s and worldwide increase in the geriatric population are driving the China’s Alzheimer’s therapeutics market.

The base year of the study is 2019, and forecasts run up to 2026.

Research Objective

• To analyze and forecast the market size of global huperzine A market.
• To classify and forecast global huperzine A market based on region.
• To identify drivers and challenges for global huperzine A market.
• To examine competitive developments such as expansions, mergers & acquisitions, etc., in global huperzine A market.
• To identify and analyze the profile of leading players operating in global huperzine A market.

The report is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities. Key target audience are:

• Manufacturers of huperzine A
• Raw material suppliers
• Market research and consulting firms
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to huperzine A

Contents

1. SUMMARY

2. OBJECTIVES OF THE STUDY

3. SCOPE OF THE REPORT

3.1 Markets Covered
3.2 Years Considered for The Report
3.3 Currency

4. MARKET RESEARCH METHODOLOGY

5. INTRODUCTION

5.1 Overview
5.2 Natural Huperzine A and Synthetic Huperzine A
5.3 Value Chain
5.4 Mechanisms of Action
5.5 Product Form (Tablet, Capsule, Injection, etc.)

6. PRODUCT PIPELINE

6.1 Wagelan/???
6.2 Yinuo/??
6.3 Shuangyiping/???
6.4 DEBIO 9902
6.5 MemorAll™
6.6 XEL 001HP

7. RULE, REGULATION AND POLICY

7.1 Regulation and Policy in China
7.2 Regulation and Policy in Other Countries

8. MARKET LANDSCAPE

8.1 Market Size and Forecast
8.2 Market by Company

9. ALZHEIMER’S DISEASE

9.1 The Basics of Alzheimer’s Disease
9.2 Stages of Alzheimer's Disease
9.3 Therapies for Alzheimer's Disease
9.4 Huperzine A in the Treatment of Alzheimer's Disease

10. HUPERZINE A MARKET BY REGION

10.1 Huperzine A Market in North America
10.2 Huperzine A Market in Europe
10.3 Huperzine A Market in China

11. DRIVERS & CHALLENGES

11.1 Market Growth Drivers
11.2 Market Challenges
11.3 Market Trends

12. PATENTS ANALYSIS

12.1 Global Huperzine A Patents Analysis
12.2 China’s Huperzine A Patents Analysis

13. KEY VENDOR ANALYSIS

13.1 Debiopharm Group
13.2 Cisen Pharmaceutical Co., Ltd.
13.3 Beijing Hwells Pharmaceutical Co., Ltd.
13.4 XYMOGEN, Inc.
13.5 Xel Pharmaceuticals, Inc.
13.6 Hainan Lingkang Pharmaceutical Co., Ltd.
13.7 Simcere Pharmaceutical Group
13.8 Henan Taloph Pharmaceutical Stock Co.
13.9 Ningbo Liwah Pharmaceutical Co., Ltd.
13.10 Ningbo Green-Health Pharma-ceutical Co., Ltd
13.11 Shanghai Fudan Forward Pharmaceutical Co., Ltd.
13.12 Shenzhen Zhonglian Pharmaceutical Co., Ltd.
13.13 Wanbang Pharmaceutical Group Co., Ltd.
13.14 Zhejiang Judu Pharmaceutical Group Co.,Ltd.
13.15 Zhejiang Zhenyuan Pharmaceutical Co., Ltd.
13.16 Yaoyou Chongqing Pharmaceutical Co., Ltd.

14. ATTACHMENT

DISCLAIMER
ABOUT GEN CONSULTING COMPANY